Drugs / SHR8554
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05928988 | Jan 2022 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05470049 | Aug → Nov 2022 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05375305 | May 2022 → Oct 2023 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT04794738 | Apr → Oct 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04766463 | Mar → Oct 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR8554 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04794738 ↗ |
| Known as | SHR8554 Injection | “SHR8554 Injection; high dose” NCT04766463 ↗1“Drug: SHR8554 Injection” NCT05375305 ↗ |
| Action | Activate | “SHR8554 is a biased agonist for µ-opioid receptors” PMID 40593123 ↗ Jul 2025 |
| Route | Intravenous | “IV SHR8554” NCT04766463 ↗ |